Based on the provided text, Anavex Life Sciences has announced positive findings from its Phase IIb/III Alzheimer’s trial, showing that its drug blarcamesine appears to slow cognitive decline to a rate comparable to that of normal aging in a specific „Precision Medicine“ population.
Key Findings
The results are based on data from a 48-week study of patients with early Alzheimer’s disease. The company focused on a genetically defined group (referred to as ABCLEAR3) with non-mutated SIGMAR1 and COL24A1 gene variants, which they estimate could include up to 70% of early Alzheimer’s patients globally.
- Cognitive Decline: On the ADAS-Cog13 scale, patients treated with blarcamesine showed an average decline of only 0.853 points over 48 weeks. This is significantly less than the 5.592-point decline observed in the placebo group, representing an 84.7% reduction in decline.
- Functional Decline: On the CDR-SB scale, the blarcamesine group showed a change of 0.465 points, which is also consistent with the decline seen in prodromal, or pre-dementia, aging.
- Comparison to Normal Aging: The company states that the measured decline on both scales for the blarcamesine group approximates the natural decline observed in older adults without dementia, suggesting the drug may be able to stabilize cognitive function rather than just slow its progression.
Mechanism of Action
Anavex reiterates that blarcamesine’s mechanism is distinct from other Alzheimer’s treatments that target amyloid and tau proteins. Instead, it works „upstream“ by activating the SIGMAR1 protein, which helps restore autophagy, a cellular process that removes damaged components. This action may provide a protective effect for brain cells.
The company plans to submit these findings for publication and present them at upcoming international Alzheimer’s conferences.